BWM
CRBP icon

Baystate Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Baystate Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$97 Buy
+16
New +$86 ﹤0.01% 1291

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baystate Wealth Management's CRBP Position: Q4 2023 in Review

Baystate Wealth Management opened a new position in Corbus Pharmaceuticals (CRBP) in Q4 2023: 16 shares worth $97. The stake represents ﹤0.01% of the portfolio and ranks #1291 among its holdings.

34 funds tracked by Wall St. Rank hold CRBP as of Q4 2023.

  • Baystate Wealth Management held 16 shares of Corbus Pharmaceuticals worth $97 as of Q4 2023.
  • Corbus Pharmaceuticals was a new Baystate Wealth Management position in Q4 2023.
  • Corbus Pharmaceuticals made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1291 holding.
  • 34 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.